Moleculin Biotech, Inc.
MBRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $4 | $3 | $4 |
| G&A Expenses | $0 | $2 | $2 | $0 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6 | $6 | $6 | $7 |
| Operating Income | -$6 | -$6 | -$6 | -$7 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$19 | -$2 | -$0 | $5 |
| Pre-Tax Income | -$25 | -$8 | -$6 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25 | -$8 | -$6 | -$2 |
| % Margin | – | – | – | – |
| EPS | -17 | -12.25 | -1,722 | -14 |
| % Growth | -38.8% | 99.3% | -12,200% | – |
| EPS Diluted | -17 | -12.25 | -1,722 | -14 |
| Weighted Avg Shares Out | 1 | 1 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 1 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$25 | -$8 | -$6 | -$2 |
| % Margin | – | – | – | – |